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Abstract
The	principle	endocannabinoids	are	2-acylglycerol	esters,	such	as	2-arachidonoylglycerol	(2-AG),	and
N-acylethanolamines,	such	as	anandamide	(N-arachidonoylethanolamine,	AEA).	The	glycerol	esters
and	ethanolamides	are	synthesised	and	hydrolysed	by	parallel,	independent	pathways.	Mechanisms
for	release	and	re-uptake	of	endocannabinoids	are	unclear,	although	potent	and	selective	inhibitors
of	facilitated	diffusion	of	endocannabinoids	across	cell	membranes	have	been	developed	[28].	FABP5
(Q01469)	has	been	suggested	to	act	as	a	canonical	intracellular	endocannabinoid	transporter	in	vivo
[17].	For	the	generation	of	2-arachidonoylglycerol,	the	key	enzyme	involved	is	diacylglycerol	lipase
(DAGL),	whilst	several	routes	for	anandamide	synthesis	have	been	described,	the	best	characterized
of	which	involves	N-acylphosphatidylethanolamine-phospholipase	D	(NAPE-PLD,	[70]).	A
transacylation	enzyme	which	forms	N-acylphosphatidylethanolamines	has	been	identified	as	a
cytosolic	enzyme,	PLA2G4E	(Q3MJ16)	[62].	In	vitro	experiments	indicate	that	the	endocannabinoids
are	also	substrates	for	oxidative	metabolism	via	cyclooxygenase,	lipoxygenase	and	cytochrome	P450
enzyme	activities	[5,	23,	72].
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